The Supreme Court this week declined to hear two pharmaceutical patent cases.

The court rejected Amarin’s try at rejuvenating its patents on its fish-oil based drug Vascepa (icosapent ethyl). A lower court had ruled in March 2020 that the company’s patents were invalid following a challenge by two generic drug companies, Hikma Pharmaceuticals and Dr. Reddy’s Laboratories.

The Supreme Court also turned away an appeal from AbbVie of a 2011 lower court ruling that the company violated federal antitrust law by pursuing a sham patent complaint against Perrigo.

The court denied that appeal and left intact the court ruling that AbbVie’s complaint against Perrigo was filed to delay a proposed generic version of AbbVie’s testosterone drug, AndroGel.